Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label adjunctive sublingual ketamine for depression or bipolar disorder with high suicide risk
RBR-472gf3Recruiting
- Sponsor
- Hospital São José
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ketamine in major depressive disorder (MDD) and bipolar disorder (BD), sponsored by Hospital São José. Started Jul 2016; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on RBR-472gf3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-472gf3.